This article first appeared on GuruFocus .
Release Date: May 13, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Schott Pharma AG & CO KGaA ( WBO:1SXP ) reported a resilient performance in the first half of the financial year 2026, with revenues reaching EUR 488 million, representing growth of 2.3% at constant currencies.
-
The Drug Containment Solutions (DCS) segment showed strong growth, with revenues increasing by 8.3% at constant currencies, driven by high-value solutions.
-
The company launched Cartridge BioPure, a new sterile glass cartridge for complex biologics, addressing key industry trends and customer needs.
-
Free cash flow more than doubled year-over-year to EUR 45.4 million, driven by working capital improvements.
-
Schott Pharma AG & CO KGaA ( WBO:1SXP ) confirmed its guidance for the full financial year 2026, expecting revenue growth of 2% to 5% at constant currencies and an EBITDA margin of around 27%.
Negative Points
-
The Drug Delivery Systems (DDS) segment faced temporary headwinds, with revenues down 5.4% at constant currencies due to weakness in polymer syringes and lower glass syringe volumes.
-
Group EBITDA in Q2 2026 declined by around EUR 7 million year-over-year, resulting in a lower EBITDA margin of 26% compared to 28.5% in Q2 2025.
-
A one-off inventory impairment on a customer-specific glass syringe negatively impacted DDS profitability.
-
The financial result showed a negative EUR 4.1 million, despite improvements due to lower interest expenses.
-
Net income decreased to EUR 64.4 million from EUR 68.1 million in the previous year, reflecting the impact of the one-off impairment and higher depreciation.
Q & A Highlights
-
Warning! GuruFocus has detected 2 Warning Sign with WBO:1SXP.
-
Is WBO:1SXP fairly valued? Test your thesis with our free DCF calculator.
Q: What are your impressions of Schott Pharma since joining as CEO, and what do you see as key levers for value creation? A: Christian Mears, CEO: Schott Pharma is a highly innovative company well-prepared to meet future pharma industry demands. The contractual changes are specific to one customer, and we are in positive discussions. I confirm the guidance for the current fiscal year, expecting a stronger second half.
Q: Can you discuss the drivers of margin for the Drug Delivery Systems (DDS) segment and confirm if the glass syringe impairment is a one-off? A: Reinhard Meyer, CFO: The glass syringe impairment is a contained impact in Q2. DDS showed good financial performance, and we expect growth momentum in both glass and polymer syringes in the second half, supporting strong operating profit.
Q: How do you see the top-line growth phasing between Q3 and Q4, and is the full guidance range on sales growth still in play? A: Reinhard Meyer, CFO: We expect growth in both Q3 and Q4, with the full guidance range still applicable. The momentum change and strong order book give us confidence in achieving the guidance.
Q: What is the outlook for the DDS segment, and can you provide more color on the one-off inventory impairment? A: Reinhard Meyer, CFO: We expect the DDS segment to be flat for the full year, with growth in the second half. The inventory impairment was for customer-specific glass syringes, and we do not foresee further risks.
Q: Could you provide insights into the growth prospects for RTU vials? A: Christian Mears, CEO: RTU vials address pharma industry needs for leaner processes and cost-effective solutions. We see them as a significant growth driver in the coming years.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
